VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Technical Scanner
RSI, Moving averages & volume momentum signals
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
Minervini — VCPContraction bases in Stage 2 uptrends
Minervini — Trend TemplateFull 8-rule Stage 2 screen
O'Neil — Cup with HandleBase breakouts with RS leadership
O'Neil — CANSLIM LeadersGrowth leaders with RS ≥ 85
Qullamaggie — High Tight FlagsPower plays after a large advance
Qullamaggie — Momentum Leaders1/3/6-month strength leaders
Livermore — Pivotal PointsMulti-touch resistance breakouts
View All Playbooks...
Breakouts
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
Breakouts
WatchlistPricing
Ctrl K
Pricing
CHE
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsCompareWatchlist
CHEChemed Corporation
$507.50$6.7B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksCHEFinancials

Chemed Corporation (CHE) Income Statement

30Y historyFree accessUpdated daily

Revenue growth rebounded to 8.8% in 2026Q2, but gross margin fell 620 basis points from 36.6% in 2024Q4 to 30.4% in 2026Q2, indicating persistent cost pressures.

Income StatementBalance SheetCash FlowRatios

CHE Income Statement

Annual statement

CHE Income Statement

Chemed Corporation (CHE) annual income statement — 30-year revenue, gross profit & net income history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99Dec'98Dec'97Dec'96
Sales/Revenue2.6B2.53B2.43B2.26B2.13B2.14B2.08B1.94B1.78B1.67B1.58B1.54B1.46B1.41B1.43B1.36B1.28B1.19B1.15B1.1B1.02B915.97M734.88M260.78M253.69M337.91M355.31M453.6M381.3M341.7M301.2M
Revenue Growth %3.31%4.06%7.37%6.06%-0.2%2.87%7.27%8.75%6.96%5.7%2.17%5.98%3.04%-1.17%5.46%5.89%7.59%3.59%4.44%8%11.2%24.64%181.8%2.79%-24.92%-4.9%-21.67%18.96%11.59%13.45%-56.92%
Cost of Goods Sold1.81B1.77B1.58B1.47B1.37B1.37B1.38B1.32B1.23B1.15B1.12B1.09B1.03B1.01B1.03B970.48M906.02M834.57M810.55M767.07M730.12M644.48M506.77M146.82M140.95M205.62M208.98M269.8M230.5M206M178.4M
COGS % of Revenue-70.03%64.86%64.72%64.16%64.02%66.27%68.15%68.87%69.03%70.74%70.47%71.05%71.38%72.26%71.57%70.75%70.12%70.55%69.73%71.68%70.36%68.96%56.3%55.56%60.85%58.82%59.48%60.45%60.29%59.23%
Gross Profit789.96M758.34M854.35M798.82M765.09M769.8M701.39M617.43M555M516.19M461.45M455.78M421.61M404.52M396.72M385.49M374.53M355.66M338.39M332.99M288.46M271.49M228.11M113.96M112.74M132.29M146.33M183.8M150.8M135.7M122.8M
Gross Margin %30.44%29.97%35.14%35.28%35.84%35.98%33.73%31.85%31.13%30.97%29.26%29.53%28.95%28.62%27.74%28.43%29.25%29.88%29.45%30.27%28.32%29.64%31.04%43.7%44.44%39.15%41.18%40.52%39.55%39.71%40.77%
Gross Profit Growth %--11.24%6.95%4.41%-0.61%9.75%13.6%11.25%7.52%11.86%1.24%8.1%4.22%1.97%2.91%2.93%5.3%5.1%1.62%15.44%6.25%19.02%100.17%1.08%-14.78%-9.59%-20.39%21.88%11.13%10.5%-49.21%
Operating Expenses440.8M417.19M487.86M458.25M421.59M426.76M311.71M360.05M311.37M403.16M282.7M271.32M253.19M271.13M240.3M231.76M231.01M229.32M205.54M210.24M183.49M194.72M170.15M105.18M95.6M141.07M116.84M157M130.7M116.1M105.4M
OpEx % of Revenue-16.49%20.07%20.24%19.75%19.95%14.99%18.57%17.47%24.19%17.93%17.58%17.39%19.18%16.8%17.09%18.04%19.27%17.89%19.11%18.01%21.26%23.15%40.34%37.68%41.75%32.88%34.61%34.28%33.98%34.99%
Selling, General & Admin440.8M417.19M424.36M395.12M358.73M366.73M330.22M305.71M271.21M276.65M248.06M237.82M222.59M215.56M208.66M202.26M201.96M197.43M175.33M184.06M161.18M157.26M147.06M95.36M85.02M104.72M103.46M136.9M113.4M100.9M93.6M
SG&A % of Revenue-16.49%17.45%17.45%16.8%17.14%15.88%15.77%15.21%16.6%15.73%15.41%15.28%15.25%14.59%14.92%15.77%16.59%15.26%16.73%15.82%17.17%20.01%36.57%33.52%30.99%29.12%30.18%29.74%29.53%31.08%
Research & Development0000000000000000000000000000000
R&D % of Revenue-------------------------------
Other Operating Expenses0063.49M63.13M62.86M60.04M-18.51M54.34M40.16M126.5M34.64M33.5M30.6M55.56M31.65M29.5M29.04M31.89M30.2M26.18M22.3M37.46M23.09M9.82M10.58M36.34M13.37M20.1M17.3M15.2M11.8M
Operating Income349.19M338.25M366.49M340.57M343.5M343.04M389.68M257.38M243.63M113.03M178.75M184.46M168.42M133.39M156.42M153.73M143.52M126.34M132.86M122.75M104.98M79.38M58.11M-7.72M-1.55M18.82M33.47M26.8M20.1M19.6M31.3M
Operating Margin %13.46%13.37%15.07%15.04%16.09%16.04%18.74%13.28%13.67%6.78%11.34%11.95%11.56%9.44%10.94%11.34%11.21%10.62%11.56%11.16%10.31%8.67%7.91%-2.96%-0.61%5.57%9.42%5.91%5.27%5.74%10.39%
Operating Income Growth %--7.71%7.61%-0.85%0.13%-11.97%51.4%5.64%115.54%-36.76%-3.09%9.52%26.26%-14.72%1.75%7.11%13.6%-4.9%8.23%16.93%32.24%36.62%852.67%-398.06%-108.24%-43.77%24.88%33.33%2.55%-37.38%-5.15%
EBITDA415.61M403.09M429.54M401.43M402.67M402.09M446.26M302.58M282.5M148.66M213.39M217.96M199.02M162.74M186.94M183.23M172.56M154.25M160.36M148.14M128.78M102.29M78.29M2.1M9.03M40.09M56.91M46.9M37.4M34.8M43.1M
EBITDA Margin %16.02%15.93%17.67%17.73%18.86%18.8%21.46%15.61%15.85%8.92%13.53%14.12%13.67%11.51%13.07%13.51%13.48%12.96%13.96%13.47%12.64%11.17%10.65%0.81%3.56%11.87%16.02%10.34%9.81%10.18%14.31%
EBITDA Growth %-3.95%-6.16%7%-0.31%0.14%-9.9%47.48%7.11%90.03%-30.33%-2.1%9.52%22.3%-12.95%2.03%6.18%11.88%-3.81%8.25%15.03%25.9%30.66%3626.23%-76.72%-77.49%-29.55%21.35%25.4%7.47%-19.26%-15.82%
D&A (Non-Cash Add-back)66.42M64.84M63.05M60.87M59.17M59.05M56.58M45.2M38.86M35.63M34.64M33.5M30.6M29.34M30.52M29.5M29.04M27.9M27.5M25.39M23.8M22.91M20.18M9.82M10.58M21.27M23.45M20.1M17.3M15.2M11.8M
EBIT365.29M357.53M401.25M353.48M334.26M352.18M398.35M266.14M244.59M121.19M180.77M183.77M170.97M138.86M160.54M154.44M145.79M132.22M127.53M113.08M104.98M76.77M57.95M8.77M17.14M15.96M29.49M26.8M20.1M19.6M17.4M
Net Interest Income2.47M7M12.83M3.16M-4.23M-1.49M-1.6M-4.02M-4.32M-3.85M-3.33M-3.36M-8.21M-14.19M-13.91M-13.46M-11.52M-11.18M-11.38M-7.94M00000000000
Interest Income7.29M8.74M14.61M6.27M355K377K757K513K671K427K383K281K0847K809K426K444K423K743K3.3M00000000000
Interest Expense4.82M1.75M1.78M3.11M4.58M1.87M2.35M4.54M4.99M4.27M3.71M3.65M8.21M15.04M14.72M13.89M11.96M11.6M5.99M11.24M00000000000
Other Income/Expense19.97M17.53M32.97M9.8M-13.82M7.28M6.31M4.23M-4.03M3.88M-1.7M-4.33M-5.67M-9.56M-12.94M-13.17M-9.69M-5.72M-10.51M-20.92M-14.7M-24.73M-21.02M7.67M-18.42M-29.14M-2.54M4.2M12M8.3M11M
Pretax Income369.16M355.78M399.46M350.37M329.68M350.31M395.99M261.61M239.6M116.92M177.05M180.13M162.75M123.83M145.82M140.56M133.83M120.62M122.34M101.84M90.28M57.28M37.09M1.25M-1.27M-10.06M33.25M31M32.1M27.9M53.6M
Pretax Margin %14.23%14.06%16.43%15.47%15.44%16.38%19.04%13.5%13.44%7.01%11.23%11.67%11.18%8.76%10.2%10.37%10.45%10.13%10.65%9.26%8.86%6.25%5.05%0.48%-0.5%-2.98%9.36%6.83%8.42%8.17%17.8%
Income Tax94.17M90.54M97.47M77.86M80.06M81.76M76.52M41.69M34.06M18.74M68.31M69.85M63.44M46.6M56.52M54.58M52M46.58M50.24M39.06M32.56M19.58M13.8M4.75M6.85M-3.36M12.66M11.3M12.2M10.8M21.9M
Effective Tax Rate %25.51%25.45%24.4%22.22%24.28%23.34%19.32%15.93%14.21%16.03%38.58%38.78%38.98%37.63%38.76%38.83%38.85%38.62%41.06%38.36%36.07%34.18%37.2%379.92%-537.02%33.41%38.09%36.45%38.01%38.71%40.86%
Net Income274.99M265.24M302M272.51M249.62M268.55M319.47M219.92M205.54M98.18M108.74M110.27M99.32M77.23M89.3M85.98M81.83M73.78M71.02M63.98M50.65M35.82M27.51M-3.44M-1.81M-10.38M20.58M19.7M19.9M30.3M32.3M
Net Margin %10.6%10.48%12.42%12.03%11.69%12.55%15.36%11.34%11.53%5.89%6.9%7.14%6.82%5.46%6.24%6.34%6.39%6.2%6.18%5.82%4.97%3.91%3.74%-1.32%-0.71%-3.07%5.79%4.34%5.22%8.87%10.72%
Net Income Growth %-5.29%-12.17%10.82%9.17%-7.05%-15.94%45.26%7%109.36%-9.72%-1.39%11.03%28.6%-13.52%3.87%5.07%10.91%3.9%11.01%26.31%41.42%30.19%900.93%-89.46%82.53%-150.4%4.49%-1%-34.32%-6.19%39.83%
Net Income (Continuing)274.99M265.24M302M272.51M249.62M268.55M319.47M219.92M205.54M98.18M108.74M110.27M99.32M77.23M89.3M85.98M81.83M74.04M72.11M62.77M57.72M36.23M19.09M11.19M11.11M-10.74M18.64M19.7M19.9M17.1M25.1M
Discontinued Operations00000000000000000000008.33M00000000
Minority Interest00000000000000000000000000000010.8M
EPS (Diluted)20.4918.4219.8917.9316.5316.8519.4813.3112.235.866.486.335.574.164.624.103.553.243.042.551.901.361.12-0.17-0.09-0.531.000.930.991.511.63
EPS Growth %2.31%-7.39%10.93%8.47%-1.9%-13.5%46.36%8.83%108.7%-9.57%2.37%13.64%33.89%-9.96%12.68%15.49%9.57%6.58%19.22%34.21%39.71%21.43%758.82%-85.39%82.7%-153%7.53%-6.06%-34.44%-7.36%38.14%
EPS (Basic)-18.4220.1018.1116.7217.1420.0213.7712.806.116.646.545.794.244.724.193.623.293.082.611.941.401.14-0.17-0.09-0.531.010.930.991.521.65
Diluted Shares Outstanding13.42M14.4M15.19M15.2M15.1M15.94M16.4M16.53M16.8M16.74M16.79M17.42M17.84M18.59M19.34M20.95M23.03M22.74M23.37M25.08M26.67M26.3M24.64M19.91M19.77M19.43M19.85M21.03M20.2M20.03M19.82M
Basic Shares Outstanding13.42M14.4M15.02M15.05M14.93M15.67M15.96M15.97M16.06M16.06M16.38M16.87M17.16M18.2M18.92M20.52M22.59M22.45M23.06M24.52M26.12M25.55M24.12M19.85M19.72M19.43M19.67M20.94M20.12M19.88M19.58M
Dividend Payout Ratio-11.95%8.97%8.62%8.82%8.2%6.6%9%9.08%17.69%15.12%14.15%14.35%18.32%14.59%14.58%14.52%11.06%7.81%9.2%12.48%17.23%20.78%---19.54%114.21%109.05%69.31%63.16%

Key Metrics

Growth RegimeStable
ProfitabilityStable
Balance SheetFortress
Cash FlowStable
Top Statement Risk

Medicare reimbursement and labor inflation

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q2)

Revenue Growth Stabilizing After Volatility

Revenue growth decelerated from 9.8% in 2025Q1 to 1.6% in 2026Q1, then rebounded to 8.8% in 2026Q2, suggesting a volatile but stabilizing trajectory. According to the latest quarterly data, the rebound appears driven by Roto-Rooter's water restoration push.

The 8.8% year-over-year growth in 2026Q2 marks a sharp acceleration from the prior quarter's 1.6%, indicating that the business may be regaining momentum. However, the 2025Q4 decline of 0.1% and the modest 3.1% growth in 2025Q3 highlight the lumpiness of demand, particularly in Roto-Rooter's emergency services. The mix shift toward higher-margin water restoration likely contributed to the rebound, but investors should monitor whether this growth rate is sustainable given the cyclical nature of plumbing services.

Gross Margin Compression Signals Structural Pressures

Gross margin fell from 36.6% in 2024Q4 to 30.4% in 2026Q2, a 620 basis point decline, according to reported financials. This suggests persistent cost pressures, likely from labor inflation and Medicare reimbursement constraints.

The steady erosion in gross margin from the mid-30s to the low-30s indicates that Chemed is facing structural headwinds. The 2025Q1 spike to 33.5% appears to be an outlier, as subsequent quarters have hovered around 30%. This trend aligns with the broader industry challenge of healthcare labor costs outpacing reimbursement updates. The company's ability to offset these pressures through Roto-Rooter's higher-margin water restoration services will be critical to stabilizing profitability.

Operating Leverage Fading as Costs Outpace Revenue

Operating margin contracted from 17.8% in 2024Q4 to 13.2% in 2026Q2, despite revenue growth, indicating negative operating leverage. As per the income statement data, SG&A has remained relatively flat while gross profit has declined, squeezing operating income.

The decline in operating margin from 17.8% to 13.2% over six quarters suggests that Chemed is not scaling its overhead efficiently. While SG&A has stayed in the $100-$115 million range, gross profit has fallen from $234 million to $204 million, implying that cost controls are not keeping pace with revenue mix changes. The 2026Q2 operating margin of 13.2% is below the 2024Q1 level of 12.3%, indicating that the company has not yet regained its pre-compression efficiency.

EPS Volatility Masks Underlying Cash Generation

Diluted EPS swung from $6.02 in 2024Q4 to $3.57 in 2025Q2, then recovered to $5.13 in 2026Q2, per quarterly filings. Stock-based compensation has been erratic, including a negative $15.2 million in 2025Q3, complicating earnings quality assessment.

The wide EPS swings, including a 23.2% year-over-year decline in 2025Q2, suggest that reported earnings are subject to significant non-operating items or one-time charges. The negative SBC in 2025Q3 is unusual and may indicate a reversal or adjustment, which warrants scrutiny. Despite these fluctuations, the company's low debt and consistent buybacks suggest that underlying cash flow remains healthy, but investors should adjust for these anomalies when forecasting future EPS.

Labor Costs and Medicare Cap Reserves Drive Expense Base

COGS as a percentage of revenue rose from 63.4% in 2024Q4 to 69.6% in 2026Q2, according to the income statement data. This increase likely reflects higher labor costs and Medicare cap reserves, which are critical to margin sustainability.

The rise in COGS ratio from 63.4% to 69.6% indicates that input costs are growing faster than revenue. For VITAS, this likely stems from nursing wage inflation and the need to set aside reserves for Medicare cap exposure. For Roto-Rooter, technician commissions and fuel costs may be contributing. Management's ability to manage these costs, particularly through productivity improvements and mix shifts, will be key to restoring margins.

2025Q1 Marks a Turning Point in Margin Trajectory

The 2025Q1 quarter saw gross margin peak at 33.5% and operating margin at 14.6%, before a sustained decline to 30.4% and 13.2% by 2026Q2. This inflection appears to signal the onset of cost pressures that have persisted.

The 2025Q1 results represent a high-water mark for profitability, with gross margin at 33.5% and operating margin at 14.6%. Subsequent quarters have seen a clear deterioration, suggesting that the company entered a period of margin compression. The 2025Q2 EPS miss and the persistent labor shortages noted in recent context flags align with this inflection, indicating that the cost environment has become more challenging. The lasting impact is a structurally lower margin profile unless management can offset these pressures.

Margin Compression and EPS Misses Undermine the Narrative

Despite raised guidance, the 2026Q2 EPS miss of $0.42 and gross margin decline from 36.6% to 30.4% over six quarters suggest that cost pressures may be more persistent than management implies. Short-sellers could argue that the company's dual-segment hedge is failing.

The most compelling bear case is that Chemed's margin compression is not temporary but structural. The gross margin decline from 36.6% to 30.4% is significant, and the EPS miss in 2026Q2, despite revenue growth, indicates that costs are outpacing revenue. If Medicare reimbursement rates continue to lag labor inflation, VITAS margins could face further erosion. Additionally, the reliance on Roto-Rooter's water restoration to offset healthcare headwinds may not be sufficient if the segment's growth is cyclical. Investors should monitor whether the raised guidance is achievable or a defensive move.

CHE — Frequently Asked Questions

Quick answers to the most common questions about buying CHE stock.

What was Chemed Corporation's (CHE) revenue in 2025?

For fiscal year 2025, Chemed Corporation (CHE) reported total revenue of $2.53B. This represents a 740.0% increase compared to $301.2M in 1996.

Is Chemed Corporation (CHE) profitable?

Chemed Corporation (CHE) is profitable, generating $265.2M in net income for the fiscal year ending 2025 with a net profit margin of 10.5%.

What is Chemed Corporation's operating profit margin?

Chemed Corporation (CHE) reported an operating income of $338.2M, resulting in an operating profit margin of 13.4%. This margin reflects the operational efficiency of the business before interest and taxes.

What is Chemed Corporation's gross profit and gross margin?

Chemed Corporation (CHE) generated $758.3M in gross profit for the year, representing a gross profit margin of 30.0%. This demonstrates the company's core pricing power and production efficiency.